Semaglutide or tirzepatide should be first-line drugs for obesity and most of its related complications, new guidance from the European Association for the Study of Obesity recommended. The authors of ...
Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback